Multimodal Biomarkers for Central Nervous System Disorders: Development, Validation, and Clinical Integration: Proceedings of a Workshop (2023)
Chapter: Appendix A: References
Appendix A
References
Albert, M. S., S. T. DeKosky, D. Dickson, B. Dubois, H. H. Feldman, N. C. Fox, A. Gamst, D. M. Holtzman, W. J. Jagust, R. C. Petersen, P. J. Snyder, M. C. Carrillo, B. Thies, and C. H. Phelps. 2011. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers & Dementia 7(3): 270-279. https://doi.org/10.1016/j.jalz.2011.03.008.
Andreasen, N., L. Minthon, E. Vanmechelen, H. Vanderstichele, P. Davidsson, B. Winblad, and K. Blennow. 1999. Cerebrospinal fluid TAU and Abeta42 as predictors of development of Alzheimer’s disease in patients with mild cognitive impairment. Neuroscience Letters 273(1):5-8. https://doi.org/10.1016/s0304-3940(99)00617-5.
Arbabshirani, M. R., S. Plis, J. Sui, and V. D. Calhoun. 2017. Single subject prediction of brain disorders in neuroimaging: Promises and pitfalls. Neuroimage 145:137-165.
Aylward, E., J. Mills, D. Liu, P. Nopoulos, C. A. Ross, R. Pierson, and J. S. Paulsen. 2011a. Association between age and striatal volume stratified by CAG repeat length in prodromal Huntington disease. PloS Currents 3:Rrn1235. https://doi.org/10.1371/currents.RRN1235.
Aylward, E. H., P. C. Nopoulos, C. A. Ross, D. R. Langbehn, R. K. Pierson, J. A. Mills, H. J. Johnson, V. A. Magnotta, A. R. Juhl, and J. S. Paulsen. 2011b. Longitudinal change in regional brain volumes in prodromal Huntington disease. Journal of Neurology, Neurosurgery, and Psychiatry 82(4):405-410. https://doi.org/10.1136/jnnp.2010.208264.
Batalle, D., A. D. Edwards, and J. O’Muircheartaigh. 2018. Annual research review: Not just a small adult brain: Understanding later neurodevelopment through imaging the neonatal brain. Journal of Child Psychology and Psychiatry 59(4):350-371. https://doi.org/10.1111/jcpp.12838.
Bayer, J. M. M., P. M. Thompson, C. R. K. Ching, M. Liu, A. Chen, A. C. Panzenhagen, N. Jahanshad, A. Marquand, L. Schmaal, and P. G. Sämann. 2022. Site effects how-to and when: an overview of retrospective techniques to accommodate site effects in multi-site neuroimaging analyses. Frontiers in Neurology 13:923988. https://doi.org/10.3389/fneur.2022.923988.
Benkert, P., S. Meier, S. Schaedelin, A. Manouchehrinia, Ö Yaldizli, A. Maceski, J. Oechtering, L. Achtnichts, D. Conen, T. Derfuss, P. H. Lalive, C. Mueller, S. Müller, Y. Naegelin, J. R. Oksenberg, C. Pot, A. Salmen, E. Willemse, I. Kockum, K. Blennow, H. Zetterberg, C. Gobbi, L. Kappos, H. Wiendl, K. Berger, M. P. Sormani, C. Granziera, F. Piehl, D. Leppert, and J. Kuhle. 2022. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: A retrospective modelling and validation study. The Lancet Neurology 21(3):246-257. https://doi.org/10.1016/s1474-4422(22)00009-6.
Berisha, V., C. Krantsevich, P. R. Hahn, S. Hahn, G. Dasarathy, P. Turaga, and J. Liss. 2021. Digital medicine and the curse of dimensionality. NPJ Digital Medicine 4(1):153. https://doi.org/10.1038/s41746-021-00521-5.
Berisha, V., and J. Liss. 2022. AI in medicine is overhyped. Scientific American. October 19.
Biglan, K. M., J. Zhang, D. Long, M. Geschwind, G. A. Kang, A. Killoran, W. Lu, E. McCusker, J. A. Mills, L. Raymond, C. Testa, J. Wojcieszek, and J. S. Paulsen. 2013. Refining the diagnosis of Huntington disease: The PREDICT-HD study. Frontiers in Aging Neuroscience 5:12. https://doi.org/10.3389/fnagi.2013.00012.
Bornhorst, J. A., D. Figdore, M. R. Campbell, V. K. Pazdernik, M. M. Mielke, R. C. Petersen, and A. Algeciras-Schimnich. 2022. Plasma neurofilament light chain (NfL) reference interval determination in an age-stratified cognitively unimpaired cohort. Clinica Chimica Acta 535:153-156. https://doi.org/10.1016/j.cca.2022.08.017.
Cagney, D. N., J. Sul, R. Y. Huang, K. L. Ligon, P. Y. Wen, and B. M. Alexander. 2018. The FDA NIH biomarkers, endpoints, and other tools (BEST) resource in neuro-oncology. Neuro-Oncology 20(9):1162-1172. https://doi.org/10.1093/neuonc/nox242.
Caron, N. S., A. S. Haqqani, A. Sandhu, A. E. Aly, H. Findlay Black, J. N. Bone, J. L. McBride, A. Abulrob, D. Stanimirovic, B. R. Leavitt, and M. R. Hayden. 2022. Cerebrospinal fluid biomarkers for assessing Huntington disease onset and severity. Brain Communications 4(6):fcac309. https://doi.org/10.1093/braincomms/fcac309.
Casella, C., I. Lipp, A. Rosser, D. K. Jones, and C. Metzler-Baddeley. 2020. A critical review of white matter changes in Huntington’s disease. Movement Disorders 35(8):1302-1311. https://doi.org/10.1002/mds.28109.
Cetin Karayumak, S., S. Bouix, L. Ning, A. James, T. Crow, M. Shenton, M. Kubicki, and Y. Rathi. 2019. Retrospective harmonization of multi-site diffusion MRI data acquired with different acquisition parameters. Neuroimage 184:180-200. https://doi.org/10.1016/j.neuroimage.2018.08.073.
del Campo, M., B. Mollenhauer, A. Bertolotto, S. Engelborghs, H. Hampel, A. H. Simonsen, E. Kapaki, N. Kruse, N. Le Bastard, S. Lehmann, J. L. Molinuevo, L. Parnetti, A. Perret-Liaudet, J. Sáez-Valero, E. Saka, A. Urbani, E. Vanmechelen, M. Verbeek, P. J. Visser, and C. Teunissen. 2012. Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: An update. Biomarkers in Medicine 6(4):419-430. https://doi.org/10.2217/bmm.12.46.
Dennis, E. L., F. Keleher, D. F. Tate, and E. A. Wilde. 2023. The role of neuroimaging in evolving TBI research and clinical practice. medRxiv. https://doi.org/10.1101/2023.02.24.23286258.
Di Martino, A., D. O’Connor, B. Chen, K. Alaerts, J. S. Anderson, M. Assaf, J. H. Balsters, L. Baxter, A. Beggiato, S. Bernaerts, L. M. Blanken, S. Y. Bookheimer, B. B. Braden, L. Byrge, F. X. Castellanos, M. Dapretto, R. Delorme, D. A. Fair, I. Fishman, J. Fitzgerald, L. Gallagher, R. J. Keehn, D. P. Kennedy, J. E. Lainhart, B. Luna, S. H. Mostofsky, R. A. Müller, M. B. Nebel, J. T. Nigg, K. O’Hearn, M. Solomon, R. Toro, C. J. Vaidya, N. Wenderoth, T. White, R. C. Craddock, C. Lord, B. Leventhal, and M. P. Milham. 2017. Enhancing studies of the connectome in autism using the autism brain imaging data exchange II. Scientific Data 4:170010. https://doi.org/10.1038/sdata.2017.10.
Di Martino, A., C. G. Yan, Q. Li, E. Denio, F. X. Castellanos, K. Alaerts, J. S. Anderson, M. Assaf, S. Y. Bookheimer, M. Dapretto, B. Deen, S. Delmonte, I. Dinstein, B. Ertl-Wagner, D. A. Fair, L. Gallagher, D. P. Kennedy, C. L. Keown, C. Keysers, J. E. Lainhart, C. Lord, B. Luna, V. Menon, N. J. Minshew, C. S. Monk, S. Mueller, R. A. Müller, M. B. Nebel, J. T. Nigg, K. O’Hearn, K. A. Pelphrey, S. J. Peltier, J. D. Rudie, S. Sunaert, M. Thioux, J. M. Tyszka, L. Q. Uddin, J. S. Verhoeven, N. Wenderoth, J. L. Wiggins, S. H. Mostofsky, and M. P. Milham. 2014. The autism brain imaging data exchange: Towards a large-scale evaluation of the intrinsic brain architecture in autism. Molecular Psychiatry 19(6):659-667. https://doi.org/10.1038/mp.2013.78.
Estevez-Fraga, C., R. Scahill, G. Rees, S. J. Tabrizi, and S. Gregory. 2020. Diffusion imaging in Huntington’s disease: Comprehensive review. Journal of Neurology, Neurosurgery, and Psychiatry 92(1):62-69. https://doi.org/10.1136/jnnp-2020-324377.
FDA (Food and Drug Administration). 2017. Guidance document: Formal meetings between the FDA and sponsors or applicants of PDUFA products guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formal-meetings-between-fda-and-sponsors-or-applicants-pdufa-products-guidance-industry (accessed April 16, 2023).
FDA. 2018. Speech: Remarks to the alliance for regenerative medicine’s annual board meeting. https://www.fda.gov/news-events/speeches-fda-officials/remarks-alliance-regenerative-medicines-annual- board-meeting-05222018 (accessed April 16, 2023).
FDA. 2019. Demonstrating substantial evidence of effectiveness for human drug and biological products: Draft guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/demonstrating-substantial-evidence-effectiveness-human-drug-and-biological-products (accessed April 16, 2023).
FDA. 2021. List of qualified biomarkers. https://www.fda.gov/drugs/biomarker-qualification-program/list-qualified-biomarkers (accessed April 16, 2023).
FDA. 2022. FDA public meeting: Identification of concepts and terminology for multi-component biomarkers. https://www.fda.gov/drugs/news-events-human-drugs/fda-public-meeting-identification-concepts-and- terminology-multi-component-biomarkers-03232022 (accessed April 16, 2023).
FDA—National Institutes of Health Biomarker Working Group. 2016. BEST (Biomarkers, EndpointS, and other Tools) resource. Silver Spring, MD, Bethesda, MD: Food and Drug Administration, National Institutes of Health.
Fitzgerald, K. C., E. S. Sotirchos, M. D. Smith, H. N. Lord, A. DuVal, E. M. Mowry, and P. A. Calabresi. 2022. Contributors to serum NfL levels in people without neurologic disease. Annals of Neurology 92(4):688-698. https://doi.org/10.1002/ana.26446.
Floris, D. L., J. O. A. Filho, M. C. Lai, S. Giavasis, M. Oldehinkel, M. Mennes, T. Charman, J. Tillmann, G. Dumas, C. Ecker, F. Dell’Acqua, T. Banaschewski, C. Moessnang, S. Baron-Cohen, S. Durston, E. Loth, D. G. M. Murphy, J. K. Buitelaar, C. F. Beckmann, M. P. Milham, and A. Di Martino. 2021. Towards robust and replicable sex differences in the intrinsic brain function of autism. Molecular Autism 12(1):19. https://doi.org/10.1186/s13229-021-00415-z.
Frost, R., P. Wighton, F. I. Karahanoğlu, R. L. Robertson, P. E. Grant, B. Fischl, M. D. Tisdall, and A. van der Kouwe. 2019. Markerless high-frequency prospective motion correction for neuroanatomical MRI. Magnetic Resonance in Medicine 82(1):126-144. https://doi.org/10.1002/mrm.27705.
Gaffney, T. 2023. Predictive biomarkers could ease the exhaustive trial-and-error of antidepressants. STAT News. Jan 24. https://www.statnews.com/2023/01/24/predictive-biomarkers-antidepressants-depression-ssri/.
GBD (Global Burden of Disease) Study. 2022. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry 9(2):137-150. https://doi.org/10.1016/s2215-0366(21)00395-3.
GeM-HD Consortium (Genetic Modifiers of Huntington’s Disease Consortium). 2015. Identification of genetic factors that modify clinical onset of Huntington’s disease. Cell 162(3):516-526. https://doi.org/10.1016/j.cell.2015.07.003.
Goergen, S. K., H. Ang, F. Wong, E. A. Carse, M. Charlton, R. Evans, G. Whiteley, J. Clark, D. Shipp, D. Jolley, E. Paul, and J. L. Cheong. 2014. Early MRI in term infants with perinatal hypoxic-ischaemic brain injury: Interobserver agreement and MRI predictors of outcome at 2 years. Clinical Radiology 69(1):72-81. https://doi.org/10.1016/j.crad.2013.09.001.
Goldsack, J. C., A. Coravos, J. P. Bakker, B. Bent, A. V. Dowling, C. Fitzer-Attas, A. Godfrey, J. G. Godino, N. Gujar, E. Izmailova, C. Manta, B. Peterson, B. Vandendriessche, W. A. Wood, K. W. Wang, and J. Dunn. 2020. Verification, analytical validation, and clinical validation (V3): The foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs). NPJ Digital Medicine 3:55. https://doi.org/10.1038/s41746-020-0260-4.
Goldstein-Piekarski, A. N., T. M. Ball, Z. Samara, B. R. Staveland, A. S. Keller, S. L. Fleming, K. A. Grisanzio, B. Holt-Gosselin, P. Stetz, J. Ma, and L. M. Williams. 2022. Mapping neural circuit biotypes to symptoms and behavioral dimensions of depression and anxiety. Biological Psychiatry 91(6):561-571. https://doi.org/10.1016/j.biopsych.2021.06.024.
Grieve, S. M., M. S. Korgaonkar, A. Etkin, A. Harris, S. H. Koslow, S. Wisniewski, A. F. Schatzberg, C. B. Nemeroff, E. Gordon, and L. M. Williams. 2013. Brain imaging predictors and the international study to predict optimized treatment for depression: Study protocol for a randomized controlled trial. Trials 14:224. https://doi.org/10.1186/1745-6215-14-224.
Grzadzinski, R., M. Huerta, and C. Lord. 2013. DSM-5 and autism spectrum disorders (ASDs): an opportunity for identifying ASD subtypes. Molecular Autism 4(1):12. https://doi.org/10.1186/2040-2392-4-12.
Hack, L. M., L. Tozzi, S. Zenteno, A. M. Olmsted, R. Hilton, J. Jubeir, M. S. Korgaonkar, A. F. Schatzberg, J. A. Yesavage, and R. O’Hara. 2023. A cognitive biotype of depression and symptoms, behavior measures, neural circuits, and differential treatment outcomes: A prespecified secondary analysis of a randomized clinical trial. JAMA Network Open 6(6):e2318411-e2318411.
Hansson, O., R. M. Edelmayer, A. L. Boxer, M. C. Carrillo, M. M. Mielke, G. D. Rabinovici, S. Salloway, R. Sperling, H. Zetterberg, and C. E. Teunissen. 2022. The Alzheimer’s Association appropriate use recommendations for blood biomarkers in Alzheimer’s disease. Alzheimers Dementia 18(12):2669-2686. https://doi.org/10.1002/alz.12756.
He, S., Y. Feng, P. E. Grant, and Y. Ou. 2022. Deep relation learning for regression and its application to brain age estimation. IEEE Transactions on Medical Imaging 41(9):2304-2317. https://doi.org/10.1109/tmi.2022.3161739.
He, S., D. Pereira, J. David Perez, R. L. Gollub, S. N. Murphy, S. Prabhu, R. Pienaar, R. L. Robertson, P. Ellen Grant, and Y. Ou. 2021. Multi-channel attention-fusion neural network for brain age estimation: Accuracy, generality, and interpretation with 16,705 healthy MRIs across lifespan. Medical Image Analysis 72:102091. https://doi.org/10.1016/j.media.2021.102091.
Heinzel, S., D. Berg, T. Gasser, H. Chen, C. Yao, and R. Postuma. 2019. Prodromal PD calculator: a web-based medical calculator for prodromal risk in parkinsonism. https://www.movementdisorders.org/MDS/Members-Only/Prodromal-PD-Calculator.htm: International Parkinson and Movement Disorder Society.
Hong, E. P., M. J. Chao, T. Massey, B. McAllister, S. Lobanov, L. Jones, P. Holmans, S. Kwak, M. Orth, M. Ciosi, D. G. Monckton, J. D. Long, D. Lucente, V. C. Wheeler, M. E. MacDonald, J. F. Gusella, and J. M. Lee. 2021. Association analysis of chromosome x to identify genetic modifiers of Huntington’s disease. Journal of Huntington’s Disease 10(3):367-375. https://doi.org/10.3233/jhd-210485.
Jack, C. R., Jr., D. A. Bennett, K. Blennow, M. C. Carrillo, B. Dunn, S. B. Haeberlein, D. M. Holtzman, W. Jagust, F. Jessen, J. Karlawish, E. Liu, J. L. Molinuevo, T. Montine, C. Phelps, K. P. Rankin, C. C. Rowe, P. Scheltens, E. Siemers, H. M. Snyder, and R. Sperling. 2018. NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dementia 14(4):535-562. https://doi.org/10.1016/j.jalz.2018.02.018.
Kalia, L. V., and A. E. Lang. 2015. Parkinson’s disease. Lancet 386(9996):896-912. https://doi.org/10.1016/s0140-6736(14)61393-3.
Kas, M. J., B. Penninx, B. Sommer, A. Serretti, C. Arango, and H. Marston. 2019. A quantitative approach to neuropsychiatry: The why and the how. Neuroscience & Biobehavioral Reviews 97:3-9. https://doi.org/10.1016/j.neubiorev.2017.12.008.
Khalil, M., C. E. Teunissen, M. Otto, F. Piehl, M. P. Sormani, T. Gattringer, C. Barro, L. Kappos, M. Comabella, F. Fazekas, A. Petzold, K. Blennow, H. Zetterberg, and J. Kuhle. 2018. Neurofilaments as biomarkers in neurological disorders. Nature Reviews Neurology 14(10):577-589. https://doi.org/10.1038/s41582-018-0058-z.
Kinnunen, K. M., A. P. Mullin, D. Pustina, E. C. Turner, J. Burton, M. F. Gordon, R. I. Scahill, E. C. Gantman, S. Noble, K. Romero, N. Georgiou-Karistianis, and A. J. Schwarz. 2021. Recommendations to optimize the use of volumetric MRI in Huntington’s disease clinical trials. Frontiers in Neurology 12:712565. https://doi.org/10.3389/fneur.2021.712565.
Klunk, W. E., H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, D. P. Holt, M. Bergström, I. Savitcheva, G. F. Huang, S. Estrada, B. Ausén, M. L. Debnath, J. Barletta, J. C. Price, J. Sandell, B. J. Lopresti, A. Wall, P. Koivisto, G. Antoni, C. A. Mathis, and B. Långström. 2004. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Annals of Neurology 55(3):306-319. https://doi.org/10.1002/ana.20009.
Langbehn, D. R., R. R. Brinkman, D. Falush, J. S. Paulsen, and M. R. Hayden. 2004. A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clinical Genetics 65(4):267-277. https://doi.org/10.1111/j.1399-0004.2004.00241.x.
Langbehn, D. R., M. R. Hayden, and J. S. Paulsen. 2010. CAG-repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches. American Journal of Medical Genetics Part B 153b(2):397-408. https://doi.org/10.1002/ajmg.b.30992.
Lee, J. M., Y. Huang, M. Orth, T. Gillis, J. Siciliano, E. Hong, J. S. Mysore, D. Lucente, V. C. Wheeler, I. S. Seong, Z. L. McLean, J. A. Mills, B. McAllister, S. V. Lobanov, T. H. Massey, M. Ciosi, G. B. Landwehrmeyer, J. S. Paulsen, E. R. Dorsey, I. Shoulson, C. Sampaio, D. G. Monckton, S. Kwak, P. Holmans, L. Jones, M. E. MacDonald, J. D. Long, and J. F. Gusella. 2022. Genetic modifiers of Huntington disease differentially influence motor and cognitive domains. American Journal of Human Genetics 109(5):885-899. https://doi.org/10.1016/j.ajhg.2022.03.004.
Lewczuk, P., N. Ermann, U. Andreasson, C. Schultheis, J. Podhorna, P. Spitzer, J. M. Maler, J. Kornhuber, K. Blennow, and H. Zetterberg. 2018. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease. Alzheimers Research and Therapy 10(1):71. https://doi.org/10.1186/s13195-018-0404-9.
Liss, J. M., S. LeGendre, and A. J. Lotto. 2010. Discriminating dysarthria type from envelope modulation spectra. Journal of Speech, Language, and Hearing Research 53(5):1246-1255. https://doi.org/10.1044/1092-4388(2010/09-0121).
Lleó, A. 2021. Biomarkers in neurological disorders: a fast-growing market. Brain Communications 3(2):fcab086. https://doi.org/10.1093/braincomms/fcab086.
Lotan, A., M. Fenckova, J. Bralten, A. Alttoa, L. Dixson, R. W. Williams, and M. van der Voet. 2014. Neuroinformatic analyses of common and distinct genetic components associated with major neuropsychiatric disorders. Frontiers of Neuroscience 8:331. https://doi.org/10.3389/fnins.2014.00331.
Mandrekar, S. J., and D. J. Sargent. 2011. All-comers versus enrichment design strategy in phase ii trials. Journal of Thoracic Oncology 6(4):658-660.
Margolis, R. J. 2016. Facilitating biomarker development: Strategies for scientific communication, pathway prioritization, data-sharing, and stakeholder collaboration. Duke-Margolis Center for Health Policy.
Martínez-Torteya, A., V. Treviño, and J. G. Tamez-Peña. 2015. Improved diagnostic multimodal biomarkers for Alzheimer’s disease and mild cognitive impairment. Biomedical Research International 2015:961314. https://doi.org/10.1155/2015/961314.
Mattsson, N., U. Andreasson, H. Zetterberg, and K. Blennow. 2017. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. Journal of the American Medical Association in Neurology 74(5):557-566. https://doi.org/10.1001/jamaneurol.2016.6117.
Mattsson, N., N. C. Cullen, U. Andreasson, H. Zetterberg, and K. Blennow. 2019. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. Journal of the American Medical Association in Neurology 76(7):791-799. https://doi.org/10.1001/jamaneurol.2019.0765.
McKhann, G., D. Drachman, M. Folstein, R. Katzman, D. Price, and E. M. Stadlan. 1984. Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology 34(7):939-944. https://doi.org/10.1212/wnl.34.7.939.
McKhann, G. M., D. S. Knopman, H. Chertkow, B. T. Hyman, C. R. Jack, Jr., C. H. Kawas, W. E. Klunk, W. J. Koroshetz, J. J. Manly, R. Mayeux, R. C. Mohs, J. C. Morris, M. N. Rossor, P. Scheltens, M. C. Carrillo, B. Thies, S. Weintraub, and C. H. Phelps. 2011. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dementia 7(3):263-269. https://doi.org/10.1016/j.jalz.2011.03.005.
Mielke, M. M., J. A. Syrjanen, K. Blennow, H. Zetterberg, P. Vemuri, I. Skoog, M. M. Machulda, W. K. Kremers, D. S. Knopman, C. Jack, Jr., R. C. Petersen, and S. Kern. 2019. Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures. Neurology 9 3(3):e252-e260. https://doi.org/10.1212/wnl.0000000000007767.
Nabers, A., L. Perna, J. Lange, U. Mons, J. Schartner, J. Güldenhaupt, K. U. Saum, S. Janelidze, B. Holleczek, D. Rujescu, O. Hansson, K. Gerwert, and H. Brenner. 2018. Amyloid blood biomarker detects Alzheimer’s disease. EMBO Molecular Medicine 10(5). https://doi.org/10.15252/emmm.201708763.
Nakamura, A., N. Kaneko, V. L. Villemagne, T. Kato, J. Doecke, V. Doré, C. Fowler, Q. X. Li, R. Martins, C. Rowe, T. Tomita, K. Matsuzaki, K. Ishii, K. Ishii, Y. Arahata, S. Iwamoto, K. Ito, K. Tanaka, C. L. Masters, and K. Yanagisawa. 2018. High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature 554(7691):249-254. https://doi.org/10.1038/nature25456.
NINDS (National Institute of Neurological Disorders and Stroke). 2023. Focus on biomarkers research. https://www.ninds.nih.gov/current-research/focus-tools-topics/focus-biomarkers-research (accessed April 28, 2023).
Onicas, A. I., A. L. Ware, A. D. Harris, M. H. Beauchamp, C. Beaulieu, W. Craig, Q. Doan, S. B. Freedman, B. G. Goodyear, R. Zemek, K. O. Yeates, and C. Lebel. 2022. Multisite harmonization of structural DTI networks in children: An A-CAP study. Frontiers of Neurology 13:850642. https://doi.org/10.3389/fneur.2022.850642.
Onnela, J. P. 2021. Opportunities and challenges in the collection and analysis of digital phenotyping data. Neuropsychopharmacology 46(1):45-54. https://doi.org/10.1038/s41386-020-0771-3.
Onnela, J. P., and S. L. Rauch. 2016. Harnessing smartphone-based digital phenotyping to enhance behavioral and mental health. Neuropsychopharmacology 41(7):1691-1696. https://doi.org/10.1038/npp.2016.7.
Ou, Y., L. Zöllei, K. Retzepi, V. Castro, S. V. Bates, S. Pieper, K. P. Andriole, S. N. Murphy, R. L. Gollub, and P. E. Grant. 2017. Using clinically acquired MRI to construct age-specific ADC atlases: Quantifying spatiotemporal ADC changes from birth to 6-year old. Human Brain Mapping 38(6):3052-3068. https://doi.org/10.1002/hbm.23573.
Ovod, V., K. N. Ramsey, K. G. Mawuenyega, J. G. Bollinger, T. Hicks, T. Schneider, M. Sullivan, K. Paumier, D. M. Holtzman, J. C. Morris, T. Benzinger, A. M. Fagan, B. W. Patterson, and R. J. Bateman. 2017. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dementia 13(8):841-849. https://doi.org/10.1016/j.jalz.2017.06.2266.
Penney, J. B., Jr., J. P. Vonsattel, M. E. MacDonald, J. F. Gusella, and R. H. Myers. 1997. CAG repeat number governs the development rate of pathology in Huntington’s disease. Annals of Neurology 41(5):689-692. https://doi.org/10.1002/ana.410410521.
Pini, L., C. Jacquemot, A. Cagnin, F. Meneghello, C. Semenza, D. Mantini, and A. Vallesi. 2020. Aberrant brain network connectivity in presymptomatic and manifest Huntington’s disease: A systematic review. Human Brain Mapping 41(1):256-269. https://doi.org/10.1002/hbm.24790.
Quatieri, T. F., J. R. Williamson, C. J. Smalt, J. Perricone, T. Patel, L. Brattain, B. Helfer, D. Mehta, J. Palmer, and K. Heaton. 2017. Multimodal biomarkers to discriminate cognitive state. The Role of Technology in Clinical Neuropsychology 409.
Regnault, A., B. Boroojerdi, J. Meunier, M. Bani, T. Morel, and S. Cano. 2019. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort. Journal of Neurology 266(8):1927-1936. https://doi.org/10.1007/s00415-019-09348-3.
Reilmann, R., B. R. Leavitt, and C. A. Ross. 2014. Diagnostic criteria for Huntington’s disease based on natural history. Movement Disorders 29(11):1335-1341. https://doi.org/10.1002/mds.26011.
Rodrigues, F. B., L. M. Byrne, R. Tortelli, E. B. Johnson, P. A. Wijeratne, M. Arridge, E. De Vita, N. Ghazaleh, R. Houghton, H. Furby, D. C. Alexander, S. J. Tabrizi, S. Schobel, R. I. Scahill, A. Heslegrave, H. Zetterberg, and E. J. Wild. 2020. Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington’s disease. Science Translational Medicine 12(574). https://doi.org/10.1126/scitranslmed.abc2888.
Ross, C. A., R. Reilmann, F. Cardoso, E. A. McCusker, C. M. Testa, J. C. Stout, B. R. Leavitt, Z. Pei, B. Landwehrmeyer, A. Martinez, J. Levey, T. Srajer, J. Bang, and S. J. Tabrizi. 2019. Movement disorder society task force viewpoint: Huntington’s disease diagnostic categories. Movement Disorders in Clinical Practice 6(7):541-546. https://doi.org/10.1002/mdc3.12808.
Saris, I. M. J., M. Aghajani, L. M. Reus, P. J. Visser, Y. Pijnenburg, N. J. A. van der Wee, A. C. Bilderbeck, A. Raslescu, A. Malik, M. Mennes, S. Koops, C. Arrango, J. L. Ayuso-Mateos, G. R. Dawson, H. Marston, M. J. Kas, and Bwjh Penninx. 2022. Social dysfunction is transdiagnostically associated with default mode network dysconnectivity in schizophrenia and Alzheimer’s disease. World Journal of Biological Psychiatry 23(4):264-277. https://doi.org/10.1080/15622975.2021.1966714.
Schwartz, M., D. Groshar, R. Inzelberg, and S. Hocherman. 2004. Dopamine-transporter imaging and visuo-motor testing in essential tremor, practical possibilities for detection of early stage Parkinson’s disease. Parkinsonism Related Disorders 10(6):385-389. https://doi.org/10.1016/j.parkreldis.2004.03.004.
Shahnawaz, M., A. Mukherjee, S. Pritzkow, N. Mendez, P. Rabadia, X. Liu, B. Hu, A. Schmeichel, W. Singer, G. Wu, A. L. Tsai, H. Shirani, K. P. R. Nilsson, P. A. Low, and C. Soto. 2020. Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature 578(7794):273-277. https://doi.org/10.1038/s41586-020-1984-7.
Simrén, J., U. Andreasson, J. Gobom, M. Suarez Calvet, B. Borroni, C. Gillberg, L. Nyberg, R. Ghidoni, E. Fernell, M. Johnson, H. Depypere, C. Hansson, I. H. Jonsdottir, H. Zetterberg, and K. Blennow. 2022. Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5-90 years. Brain Communication 4(4):fcac174. https://doi.org/10.1093/braincomms/fcac174.
Sotirchos, E. S., K. C. Fitzgerald, C. M. Singh, M. D. Smith, M. Reyes-Mantilla, C. M. Hersh, M. H. Hyland, R. Canissario, S. B. Simmons, G. Arrambide, X. Montalban, M. Comabella, R. T. Naismith, M. Qiao, L. B. Krupp, J. A. Nicholas, K. Akgün, T. Ziemssen, R. Rudick, E. Fisher, R. A. Bermel, E. M. Mowry, and P. A. Calabresi. 2023. Associations of sNfL with clinico-radiological measures in a large MS population. Annals of Clinical Translational Neurology 10(1):84-97. https://doi.org/10.1002/acn3.51704.
Sperling, R. A., P. S. Aisen, L. A. Beckett, D. A. Bennett, S. Craft, A. M. Fagan, T. Iwatsubo, C. R. Jack, Jr., J. Kaye, T. J. Montine, D. C. Park, E. M. Reiman, C. C. Rowe, E. Siemers, Y. Stern, K. Yaffe, M. C. Carrillo, B. Thies, M. Morrison-Bogorad, M. V. Wagster, and C. H. Phelps. 2011. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dementia 7(3):280-292. https://doi.org/10.1016/j.jalz.2011.03.003.
Stegmann, G., S. Hahn, S. Bhandari, K. Kawabata, J. Shefner, C. J. Duncan, J. Liss, V. Berisha, and K. Mueller. 2022. Automated semantic relevance as an indicator of cognitive decline: Out-of-sample validation on a large-scale longitudinal dataset. Alzheimers Dementia 14(1):e12294. https://doi.org/10.1002/dad2.12294.
Stegmann, G. M., S. Hahn, C. J. Duncan, S. B. Rutkove, J. Liss, J. M. Shefner, and V. Berisha. 2021. Estimation of forced vital capacity using speech acoustics in patients with ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 22(sup1):14-21. https://doi.org/10.1080/21678421.2020.1866013.
Stegmann, G. M., S. Hahn, J. Liss, J. Shefner, S. Rutkove, K. Shelton, C. J. Duncan, and V. Berisha. 2020. Early detection and tracking of bulbar changes in ALS via frequent and remote speech analysis. NPJ Digital Medicine 3:132. https://doi.org/10.1038/s41746-020-00335-x.
Tabrizi, S. J., S. Schobel, E. C. Gantman, A. Mansbach, B. Borowsky, P. Konstantinova, T. A. Mestre, J. Panagoulias, C. A. Ross, M. Zauderer, A. P. Mullin, K. Romero, S. Sivakumaran, E. C. Turner, J. D. Long, and C. Sampaio. 2022. A biological classification of Huntington’s disease: The integrated staging system. Lancet Neurology 21(7):632-644. https://doi.org/10.1016/s1474-4422(22)00120-x.
Tan, B., R. Shishegar, G. R. Poudel, A. Fornito, and N. Georgiou-Karistianis. 2021. Cortical morphometry and neural dysfunction in Huntington’s disease: A review. European Journal of Neurology 28(4):1406-1419. https://doi.org/10.1111/ene.14648.
Tang, S., N. Sun, D. L. Floris, X. Zhang, A. Di Martino, and B. T. T. Yeo. 2020. Reconciling dimensional and categorical models of autism heterogeneity: A brain connectomics and behavioral study. Biological Psychiatry 87(12):1071-1082. https://doi.org/10.1016/j.biopsych.2019.11.009.
Tanner, C. M. 2020. Exploring the clinical burden of OFF periods in Parkinson disease. American Journal of Managed Care 26(12 Suppl):S255-S64. https://doi.org/10.37765/ajmc.2020.88517.
Torous, J., M. V. Kiang, J. Lorme, and J. P. Onnela. 2016. New tools for new research in psychiatry: A scalable and customizable platform to empower data driven smartphone research. Journal of Medical Internet Research Mental Health 3(2):e16. https://doi.org/10.2196/mental.5165.
Traut, N., K. Heuer, G. Lemaître, A. Beggiato, D. Germanaud, M. Elmaleh, A. Bethegnies, L. Bonnasse-Gahot, W. Cai, S. Chambon, F. Cliquet, A. Ghriss, N. Guigui, A. de Pierrefeu, M. Wang, V. Zantedeschi, A. Boucaud, J. van den Bossche, B. Kegl, R. Delorme, T. Bourgeron, R. Toro, and G. Varoquaux. 2022. Insights from an autism imaging biomarker challenge: Promises and threats to biomarker discovery. Neuroimage 255:119171. https://doi.org/10.1016/j.neuroimage.2022.119171.
Vabalas, A., E. Gowen, E. Poliakoff, and A. J. Casson. 2019. Machine learning algorithm validation with a limited sample size. PLoS One 14(11):e0224365. https://doi.org/10.1371/journal.pone.0224365.
Vermunt, L., M. Otte, I. M. W. Verberk, J. Killestein, A. W. Lemstra, W. M. van der Flier, Y. A. L. Pijnenburg, E. G. B. Vijverberg, F. H. Bouwman, G. Gravesteijn, W. D. J. van de Berg, P. Scheltens, A. C. van Harten, E. A. J. Willemse, and C. E. Teunissen. 2022. Age- and disease-specific reference values for neurofilament light presented in an online interactive support interface. Annals of Clinical Translational Neurology 9(11):1832-1837. https://doi.org/10.1002/acn3.51676.
Walhovd, K. B., A. M. Fjell, J. Brewer, L. K. McEvoy, C. Fennema-Notestine, D. J. Hagler, Jr., R. G. Jennings, D. Karow, and A. M. Dale. 2010. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. American Journal of Neuroradiology 31(2):347-354. https://doi.org/10.3174/ajnr.A1809.
Wijeratne, P. A., S. Garbarino, S. Gregory, E. B. Johnson, R. I. Scahill, J. S. Paulsen, S. J. Tabrizi, M. Lorenzi, and D. C. Alexander. 2021. Revealing the timeline of structural MRI changes in premanifest to manifest Huntington disease. Neurological Genetics 7(5):e617. https://doi.org/10.1212/nxg.0000000000000617.
Williams, L. M., A. J. Rush, S. H. Koslow, S. R. Wisniewski, N. J. Cooper, C. B. Nemeroff, A. F. Schatzberg, and E. Gordon. 2011. International study to predict optimized treatment for depression (iSPOT-D), a randomized clinical trial: Rationale and protocol. Trials 12:4. https://doi.org/10.1186/1745-6215-12-4.
Zhang, D., Y. Wang, L. Zhou, H. Yuan, and D. Shen. 2011a. Multimodal classification of Alzheimer’s disease and mild cognitive impairment. Neuroimage 55(3):856-867. https://doi.org/10.1016/j.neuroimage.2011.01.008.
Zhang, Y., J. D. Long, J. A. Mills, J. H. Warner, W. Lu, and J. S. Paulsen. 2011b. Indexing disease progression at study entry with individuals at-risk for Huntington disease. American Journal of Medical Genetics - Part A (7):751-763. https://doi.org/10.1002/ajmg.b.31232.
Zhou, W., J. Zhang, F. Ye, G. Xu, H. Su, Y. Su, and X. Zhang. 2017. Plasma neurofilament light chain levels in Alzheimer’s disease. Neuroscience Letters 650:60-64. https://doi.org/10.1016/j.neulet.2017.04.027.
Zolfaghari, S., A. E. Thomann, N. Lewandowski, D. Trundell, F. Lipsmeier, G. Pagano, K. I. Taylor, and R. B. Postuma. 2022. Self-report versus clinician examination in early Parkinson’s disease. Movement Disorders 37(3):585-597. https://doi.org/10.1002/mds.28884.
